DE69932835D1 - Medizinische aerosolzubereitung - Google Patents

Medizinische aerosolzubereitung

Info

Publication number
DE69932835D1
DE69932835D1 DE69932835T DE69932835T DE69932835D1 DE 69932835 D1 DE69932835 D1 DE 69932835D1 DE 69932835 T DE69932835 T DE 69932835T DE 69932835 T DE69932835 T DE 69932835T DE 69932835 D1 DE69932835 D1 DE 69932835D1
Authority
DE
Germany
Prior art keywords
aerosol preparation
medical aerosol
amino acid
aerosol formulation
medicinal aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69932835T
Other languages
English (en)
Other versions
DE69932835T2 (de
Inventor
Akwete Adjei
J Cutie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeropharm Technology LLC
Original Assignee
Aeropharm Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22567809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69932835(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aeropharm Technology LLC filed Critical Aeropharm Technology LLC
Publication of DE69932835D1 publication Critical patent/DE69932835D1/de
Application granted granted Critical
Publication of DE69932835T2 publication Critical patent/DE69932835T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69932835T 1998-09-22 1999-09-17 Medizinische aerosolzubereitung Expired - Lifetime DE69932835T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09158369 US6136294C1 (en) 1998-09-22 1998-09-22 Amino acid stabilized medical aerosol formulation
US158369 1998-09-22
PCT/US1999/021510 WO2000016814A1 (en) 1998-09-22 1999-09-17 Medicinal aerosol formulation

Publications (2)

Publication Number Publication Date
DE69932835D1 true DE69932835D1 (de) 2006-09-28
DE69932835T2 DE69932835T2 (de) 2007-02-01

Family

ID=22567809

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69932835T Expired - Lifetime DE69932835T2 (de) 1998-09-22 1999-09-17 Medizinische aerosolzubereitung
DE69943360T Expired - Lifetime DE69943360D1 (de) 1998-09-22 1999-09-17 Medizinische Aerosolformulierung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69943360T Expired - Lifetime DE69943360D1 (de) 1998-09-22 1999-09-17 Medizinische Aerosolformulierung

Country Status (15)

Country Link
US (1) US6136294C1 (de)
EP (2) EP1123120B1 (de)
JP (1) JP2002526459A (de)
CN (1) CN100337614C (de)
AT (2) ATE336268T1 (de)
AU (1) AU745554B2 (de)
CA (1) CA2344816C (de)
CY (1) CY1105538T1 (de)
DE (2) DE69932835T2 (de)
DK (1) DK1123120T3 (de)
ES (1) ES2267288T3 (de)
HK (2) HK1041835A1 (de)
MX (1) MXPA01002894A (de)
PT (1) PT1123120E (de)
WO (1) WO2000016814A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6362225B1 (en) * 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
EP1292283A1 (de) * 2000-01-25 2003-03-19 Aeropharm Technology Incorporated Medizinische aerosol formulierung
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6565833B1 (en) * 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
CZ303833B6 (cs) * 2000-05-22 2013-05-22 Chiesi Farmaceutici S.P.A. Aerosolový prostredek
WO2002007672A2 (en) * 2000-07-19 2002-01-31 Aeropharm Technology, Inc. A medicinal aerosol formulation
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
AU2001275760B2 (en) * 2000-08-05 2005-03-17 Glaxo Group Limited 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6485707B2 (en) * 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
HUP0400070A2 (hu) * 2001-04-30 2004-04-28 Glaxo Group Limited 17alfa-helyzetben ciklusos észtercsoportot tartalmazó androsztán-17béta-karbotiosav-észter-származékok mint gyulladásgátló szerek, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények
JP2005500290A (ja) * 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
AU2002337803A1 (en) * 2001-10-03 2003-04-14 Glaxo Group Limited Sustained release pharmaceutical compositions
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
EP1458354A1 (de) * 2001-12-21 2004-09-22 3M Innovative Properties Company Ionenpaarkomplexe enthaltende medizinische aerosolzusammensetzung
US7186402B2 (en) * 2001-12-21 2007-03-06 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound
AU2002367032B8 (en) * 2001-12-21 2008-10-23 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
AU2003217623A1 (en) * 2002-02-20 2003-09-09 Sepracor Inc. Amino acid and peptide-modified forms of glucocorticoids
AU2003217950A1 (en) * 2002-03-05 2003-09-22 Cleveland State University Agglomerated particles for aerosol drug delivery
US20030199594A1 (en) * 2002-04-23 2003-10-23 Rasik Shah Helium propellant composition for use with aerosols
US20050203217A1 (en) * 2002-04-30 2005-09-15 Pomrink Gregory J. Stabilizers for polymerizable biocompatible materials
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
CN1292748C (zh) * 2003-03-05 2007-01-03 南昌弘益科技有限公司 噻托溴铵吸入粉雾剂及其制备工艺
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
CA2664251A1 (en) 2006-09-12 2008-03-20 Cephalin Pharmaceuticals Inc. Isovaline for treatment of pain
GB0620700D0 (en) * 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
JP5513380B2 (ja) * 2007-06-25 2014-06-04 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合剤の組成物
DE102008007198A1 (de) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201210580D0 (en) 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
WO2014099676A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN106137964A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有丙酸倍氯米松的气雾剂药物组合物
CN106138014A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有糖皮质激素的气雾剂药物组合物
CN106137965A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有环索奈德的气雾剂药物组合物
CN105534961B (zh) * 2015-12-30 2019-06-04 孙红娟 妥布霉素吸入溶液及其制备方法
CN110302158B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 一种噻托溴铵气雾剂组合物及其制备方法
CN110302184B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 赖氨酸在季铵盐类m受体拮抗剂气雾剂中的应用
CN110302157B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 一种异丙托溴铵气雾剂组合物及其制备方法
CN110742875B (zh) * 2018-07-05 2022-09-30 北京盈科瑞创新药物研究有限公司 一种吸入用吡非尼酮溶液制剂及其制备方法和应用
CN110755414A (zh) * 2019-11-12 2020-02-07 南京华盖制药有限公司 一种酒石酸阿福特罗气雾剂及其制备方法
GB2614901A (en) * 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (de) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
US3261748A (en) * 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
NL7708731A (nl) * 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US4129603A (en) * 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
AU5194990A (en) * 1989-02-23 1990-09-26 Rorer International (Holdings), Inc. Therapeutic aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
DE69231992T2 (de) * 1991-06-10 2001-12-13 Schering Corp Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
NZ244439A (en) * 1991-09-25 1994-01-26 Fisons Plc Pressurised aerosol compositions comprising hydrofluoroalkane, dispersed
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
GB9202522D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
ES2122261T3 (es) * 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
CA2176249C (en) * 1993-12-02 2010-06-01 Akwete L. Adjei Aerosol drug formulations for use with non-cfc propellants
CN1069192C (zh) * 1994-04-21 2001-08-08 王世立 一种气溶胶制剂及其配制方法
DE69530325T2 (de) * 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
AU706195B2 (en) * 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility

Also Published As

Publication number Publication date
ATE336268T1 (de) 2006-09-15
DK1123120T3 (da) 2006-10-02
EP1123120A1 (de) 2001-08-16
DE69943360D1 (de) 2011-05-26
CA2344816C (en) 2011-05-24
CN1328473A (zh) 2001-12-26
EP1731140A3 (de) 2007-06-27
MXPA01002894A (es) 2002-06-04
CA2344816A1 (en) 2000-03-30
ATE505184T1 (de) 2011-04-15
PT1123120E (pt) 2006-10-31
HK1097777A1 (en) 2007-07-06
EP1731140B1 (de) 2011-04-13
US6136294A (en) 2000-10-24
JP2002526459A (ja) 2002-08-20
DE69932835T2 (de) 2007-02-01
US6136294C1 (en) 2002-09-24
AU5926799A (en) 2000-04-10
AU745554B2 (en) 2002-03-21
CN100337614C (zh) 2007-09-19
ES2267288T3 (es) 2007-03-01
EP1731140A2 (de) 2006-12-13
EP1123120A4 (de) 2003-07-23
WO2000016814A1 (en) 2000-03-30
HK1041835A1 (en) 2002-07-26
CY1105538T1 (el) 2010-07-28
EP1123120B1 (de) 2006-08-16

Similar Documents

Publication Publication Date Title
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
MXPA03000442A (es) Una formulacion medicinal en aerosol.
HK1042444A1 (zh) 藥用噴霧製劑
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
DK0656207T4 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
FI964583A0 (fi) Tokoferolikoostumuksia biologisesti aktiivisten aineiden antamiseksi
ATE291898T1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
MY123193A (en) Novel 2-(iminomethyl)amino-phenyl derivatives,preparation,application as medicines and compositions containing same
GB0016876D0 (en) Novel formulation
CA2497171A1 (en) Water stabilized medicinal aerosol formulation
NO894616L (no) Fremgangsmaate for fremstilling av anti-aterosklerotisk aktive diarylforbindelser.
WO2002007672A3 (en) A medicinal aerosol formulation
AU1534501A (en) Pharmaceutical formulations of salmeterol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition